How do I install the Endo Sdm Antidepressant skill?

Run npx skillmds@latest add dromlakhani/endo-sdm-antidepressant in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Endo Sdm Antidepressant safe to use?

SkillMD's automated safety review verdict for this skill is PASS. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Endo Sdm Antidepressant?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Endo Sdm Antidepressant free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Endo Sdm Antidepressant?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Endo Sdm Antidepressant by dromlakhani

Name: Endo Sdm Antidepressant
Rating: 4.5 (4 reviews)
Author: dromlakhani

Endo Sdm Antidepressant

Recommends a shared decision‑making process that provides patients with quantitative estimates of the expected weight effect of antidepressants to inform drug choice, also considering expected treatment length. Triggers include clinician questions such as ‘How should I discuss weight‑change risks with this patient starting an antidepressant?’ or ‘What tool can I use to show expected weight impact of sertraline vs bupropion?’.

dromlakhani Updated Aug 19, 2026 10 repo stars

File contents

Shared decision‑making for antidepressants with weight‑effect estimates

STEP 1 — Gather Information

Collect depression diagnosis, baseline weight/BMI, comorbidities, prior antidepressant trials, expected treatment duration, and patient’s specific concerns or preferences regarding weight change.

STEP 2 — Rule In / Rule Out

If antidepressant therapy is indicated and the patient expresses concern about weight‑related side effects, proceed to weight‑effect discussion; otherwise, prescribe using standard efficacy/safety criteria without a formal weight‑effect conversation.

STEP 3 — Classify or Stratify

Stratify candidate antidepressants by published mean weight change (e.g., bupropion ≈ –1 kg, sertraline ≈ +0.5 kg, paroxetine ≈ +1–2 kg) into categories of weight loss, neutral, or gain, adjusting estimates for the anticipated length of treatment.

STEP 4 — Decide

Engage in shared decision‑making: present the quantitative weight‑effect estimates alongside efficacy, tolerability, and other side‑effect profiles; elicit patient values; select the antidepressant that best aligns with clinical goals and patient preferences; document the discussion and chosen agent.

Clinical Guardrails / Mimics / Pitfalls

Do not let weight‑effect estimates override efficacy or safety; avoid presenting mean changes as guaranteed individual outcomes; do not omit discussion of other adverse effects; do not use the estimates to pressure the patient toward a particular drug.

Concrete Clinical Example

A 45‑year‑old woman with MDD, BMI 31 kg/m², worries about weight gain and plans 6 months of treatment. The clinician shares estimates: bupropion –1 kg (loss), sertraline +0.5 kg (small gain), paroxetine +1.5 kg (moderate gain). After reviewing efficacy and side‑effects, she chooses bupropion.

Source: Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2015, DOI: 10.1210/jc.2014-3415

---name: endo-sdm-antidepressantdescription: Recommends a shared decision‑making process that provides patients with quantitative estimates of the expected weight effect of antidepressants to inform drug choice, also considering expected treatment length. Triggers include clinician questions such as ‘How should I discuss weight‑change risks with this patient starting an antidepressant?’ or ‘What tool can I use to show expected weight impact of sertraline vs bupropion?’.---# Shared decision‑making for antidepressants with weight‑effect estimates## STEP 1 — Gather InformationCollect depression diagnosis, baseline weight/BMI, comorbidities, prior antidepressant trials, expected treatment duration, and patient’s specific concerns or preferences regarding weight change.## STEP 2 — Rule In / Rule OutIf antidepressant therapy is indicated **and** the patient expresses concern about weight‑related side effects, proceed to weight‑effect discussion; otherwise, prescribe using standard efficacy/safety criteria without a formal weight‑effect conversation.## STEP 3 — Classify or StratifyStratify candidate antidepressants by published mean weight change (e.g., bupropion ≈ –1 kg, sertraline ≈ +0.5 kg, paroxetine ≈ +1–2 kg) into categories of weight loss, neutral, or gain, adjusting estimates for the anticipated length of treatment.## STEP 4 — DecideEngage in shared decision‑making: present the quantitative weight‑effect estimates alongside efficacy, tolerability, and other side‑effect profiles; elicit patient values; select the antidepressant that best aligns with clinical goals and patient preferences; document the discussion and chosen agent.## Clinical Guardrails / Mimics / PitfallsDo not let weight‑effect estimates override efficacy or safety; avoid presenting mean changes as guaranteed individual outcomes; do not omit discussion of other adverse effects; do not use the estimates to pressure the patient toward a particular drug.## Concrete Clinical ExampleA 45‑year‑old woman with MDD, BMI 31 kg/m², worries about weight gain and plans 6 months of treatment. The clinician shares estimates: bupropion –1 kg (loss), sertraline +0.5 kg (small gain), paroxetine +1.5 kg (moderate gain). After reviewing efficacy and side‑effects, she chooses bupropion.**Source:** Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2015, DOI: 10.1210/jc.2014-3415

Frequently asked questions